Positron Emission Tomography (PET) is an imaging modality used in neurology and oncology and, in some cases, used in conjunction with magnetic resonance imaging (MRI). PET defines the radiotherapeutic target volume of a tumour or the extent of disease before surgically removing a tissue structure or organ from the human body.
PET also assists in establishing a prognostic value about the patients’ overall cancer outcome, regardless of therapy, through molecular imaging. For example, the PET radiotracer fluorine-18-labelled fluoroethyltyrosine (18F-FET) has been shown to predict the prognosis of improved target delineation to assess treatment response.
A recent study using 18F-FET-PET and T1 weighted image MRI predicted the treatment effectiveness following glioblastoma patients’ chemoradiation therapy. The radiotracer fluorodopa F-18 (fluoro-deoxyphenylalanine 18F-DOPA) provides additional clinical information that histopathology may validate. Another target for brain tumour imaging is the translocator protein (TSPO).
This protein is overexpressed in glioblastoma patients, and clinical investigations have shown a link to the neuro-inflammatory component by observing a TSPO PET signal. Positron Emission Tomography is also used to evaluate head and neck cancers such as nasopharyngeal carcinomas, squamous cell cancer and salivary tumours.
Furthermore, the hybrid PET and computed tomography (CT) scanner can provide insight into the status of nodal metastases of the tumour and tissue metabolism. PET/CT enables contouring for chemotherapy and radiotherapy in radiation treatment planning. Lung cancer occurs in 80-90% of non-small cell lung cancer (NSCLC) patients. PET imaging with 18F-FDG (fluorodeoxyglucose) is used to stage NSCLC patients.
In another diagnostic investigation, PET/CT PSMA (prostate-specific membrane antigen) ligands labelled with gallium-68 or fluorine-18 are used in prostate cancer screening programmes because they provide an excellent target-to-background ratio, leading to a better detection rate. PSMA is highly specific for prostatic tumoral tissue.
You are here:
home »
The study “Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of […]
Q&A – Medical Imaging Modalities and Therapy explores innovative techniques and advancements in diagnostic and therapeutic imaging applications.
Rubidium-82 enhances PET imaging, aiding myocardial perfusion evaluation, crucial for diagnosing coronary artery disease efficiently.
Nitrogen-13 Ammonia, used in cardiac PET imaging, assesses myocardial perfusion, aiding diagnosis and treatment of heart diseases.
Exploring Nitrogen-13 Ammonia: A Vital Radiotracer in Cardiac Imaging and Beyond Read Post »
3D medical imaging transforms diagnostics and treatment, enhancing precision, patient education, and enabling AI-driven analysis and immersive experiences.
Large vessel vasculitis and polymyalgia rheumatica are both inflammatory rheumatic diseases that can result in serious illness if not diagnosed.
Diagnosis of Large Vessel Vasculitis and Polymyalgia Rheumatica with FDG-PET/CT Read Post »
Positrons, alpha particles, beta particles, and electron capture contribute to nuclear medicine, diagnostics, and diverse scientific applications.
Advanced medical imaging technologies transformed liver disease detection, diagnosis and management, enhancing diagnostic accuracy and personalized treatments.
Medical Imaging of the Liver: Techniques and Applications Read Post »
Indium-111 oxyquinoline enables diverse cellular imaging, crucial for detecting infections, thrombosis, tumours, and advancing stem cell research.
Indium-111 Oxyquinoline: A Versatile Radiopharmaceutical Agent Read Post »
Alzheimer’s disease, an age-related neurodegenerative disorder, impacts brain structure and function, requiring advanced imaging techniques for improved understanding and diagnosis.
Brain Imaging in Alzheimer’s Disease: Techniques, Advancements, and Challenges Read Post »
Gallium-68 DOTATATE, a radiopharmaceutical, targets somatostatin receptors, aiding neuroendocrine tumor detection through PET imaging, enhancing diagnostic accuracy and patient outcomes.
Gallium-68 DOTATATE: A Novel Diagnostic Tool for Neuroendocrine Tumours Read Post »
Fluorine-18 Flutemetamol, a radioactive tracer, for early detection of Alzheimer’s disease through PET imaging, enhancing diagnostic accuracy.
Fluorine-18 Flutemetamol: An Imaging Agent Revolutionising Alzheimer’s Disease Diagnosis Read Post »
Fluorine-18 Florbetaben is a radiotracer used in medical imaging to detect amyloid plaques in the brain.
Fluorine-18 Florbetaben: An Advanced Radiotracer for Alzheimer’s Disease Detection Read Post »
Theranostics is a cutting-edge approach that integrates diagnosis and therapy, enabling personalised and precise disease management.
Personalised Theranostics for Cancer: A New Era in Precision Medicine Read Post »
PET imaging is used in oncology, neurology and cardiology.
Molecular Imaging Technology: Use of PET in Clinical Microdose Studies Read Post »
Evaluation of metastatic castrate-resistant prostate cancer using fluorine-18 choline PET-CT imaging.
PET/CT images are used for detecting, staging and monitoring various malignant tumours.
PET/CT images quantification for diagnostics and radiotherapy applications Read Post »
Neuroendocrine tumours include a spectrum of neoplasms characterized by histologic heterogeneity.
[18F]-Estradiol PET/CT imaging in breast cancer patients Read Post »
